Yuri E. Nikiforov, MD, PhD, discusses the over treatment of thyroid cancer and why the incidence of this disease has been increasing over the past few decades.
Yuri E. Nikiforov, MD, PhD, professor of pathology and vice chair of Department of Pathology at the University of Pittsburgh Medical Center, discusses the over treatment of thyroid cancer and why the incidence of this disease has been increasing over the past few decades.
In the thyroid cancer space, overtreatment can be a major issue. The biggest issue is that overdiagnosis leads to overtreatment. Over the past 20 years or so, everybody was getting ultrasounds and biopsies, which ultimately led the rate of thyroid cancer to go up.
However, with the reclassification of encapsulated follicular variants of papillary thyroid cancer (EFVPTC) to noninvasive follicular thyroid neoplasm with papillary-like features (NIFTP), the overtreatment of thyroid cancer has decreased. This new histology of the thyroid, NIFTP, became reportable to the field of thyroid cancer in 2016 and with this reclassification, more treatments and follow-up are no longer necessary.
TRANSCRIPTION:
0:08 | In the last 20-25 years, the incidence of thyroid cancer has been growing very fast. Mortality stays the same with just a minimal increase because we detected a lot of tumors that have very low malignant potential, or they have even no malignant potential, or they are very low. There are things we can do to not over treat patients.
0:47 | NIFTP in fact, is 1 of the ways how we can deescalate this treatment and minimize unneeded additional treatments and additional therapy for patients. Over the last several years, we started to see the trend for decreasing the incidence of thyroid cancer. Obviously it is difficult to be sure as it has complex factors, but we believe that both a decrease in medical surveillance, and NIFTP reclassification are factors that help us to start seeing a systematically decreasing incidence of thyroid cancer in the United States and all over the world.
SELECT Trial Establishes Lenvatinib’s Role in RAI-Refractory DTC
May 2nd 2024In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Read More
Anticipating Novel Options for the RAI-Refractory DTC Armamentarium
May 15th 2023In season 4, episode 6 of Targeted Talks, Warren Swegal, MD, takes a multidisciplinary look at the RAI-refractory differentiated thyroid cancer treatment landscape, including the research behind 2 promising systemic therapy options.
Listen
Optimizing Thyroid Cancer Care: New Tools and Emerging Options
March 12th 2024Lori J. Wirth, MD, discussed advancements in diagnosing and treating thyroid cancer, offering community oncologists improved tools for identifying low-risk cancers, personalizing treatment, and exploring innovative approaches.
Read More